Interfering VE-cadherin Y685 Phosphorylation inhibits development of experimental diabetic and prediabetic retinopathy
Ontology highlight
ABSTRACT: Diabetic retinopathy involves early retinal vascular barrier breakdown and pericyte loss, yet the initiating molecular events remain poorly defined. Vascular endothelial cadherin (VE-cadherin), a key regulator of endothelial integrity, is notably reduced in diabetic and prediabetic nucleoside diphosphate kinase B (NDPKB) deficient mouse retinas, particularly in the retinal deep capillary layer, and this decline precedes pericyte loss. In vitro, high glucose (HG) and NDPKB deficiency induced VE-cadherin Y685 phosphorylation, promoting its junctional internalization, activating the hexosamine biosynthesis pathway, and increasing angiopoietin 2 (Ang2), resulting in impaired endothelial barrier function and disrupting pericyte attachment. Preventing Y685 phosphorylation through VE-cadherin Y685F mutation blocked these HG- and NDPKB-driven pathological effects. Pharmacological intervention identified protein O-linked β-N-acetylglucosamin (O-GlcNAc) modification as a mediator of Y685-dependent Ang2 upregulation. In vivo, VE-cadherin Y685F knock-in mice were protected from diabetes- and prediabetes-induced vascular hyperpermeability, exhibited reduced protein O-GlcNAcylation and Ang2 induction, and maintained neuronal function. O-GlcNAc-enriched retinal proteomics further showed that the Y685F mutation restored balanced neurovascular and mitochondrial pathways. These findings highlight the potential of targeting VE-cadherin Y685 phosphorylation as a promising therapeutic approach to maintain retinal vascular integrity and attenuate pathological progression of diabetic and prediabetic retinopathy.
INSTRUMENT(S):
ORGANISM(S): Mus Musculus (mouse)
TISSUE(S): Retina
DISEASE(S): Type 1 Diabetes Mellitus
SUBMITTER:
Yuxi Feng
LAB HEAD: Yuxi Feng
PROVIDER: PXD072047 | Pride | 2026-03-07
REPOSITORIES: Pride
ACCESS DATA